The optimal treatment of venous thrombosis: Current status and future perspectives

Clinical Laboratory

Volumn 47, Issue 3-4, 2001, Pages 151-154

  Prandoni, P ^a   Bernardi, E ^a   Bagatella, P ^a   Piccioli, A ^a   Marchiori, A ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; HOME CARE; HUMAN; LONG TERM CARE; PATIENT EDUCATION; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SELF INJECTION; SHORT COURSE THERAPY; THROMBOCYTOPENIA;

AMBULATORY CARE; ANTICOAGULANTS; CLINICAL TRIALS; HUMANS; VENOUS THROMBOSIS;

EID: 0035076283     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis
2. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism. An overview
3. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis
4. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis
5. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
6. Fixed-dose, body weight-independent subcutaneous LMWH versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis
7. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
8. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
9. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis
10. Replacing inpatient care by outpatient care in the treatment of deep-venous thrombosis. An economic evaluation
11. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin
12. Out-patient treatment of acute deep vein thrombosis
13. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection
14. Home treatment of deep vein thrombosis: A two-year experience of a single institution
15. Antithrombotic therapy for venous thromboembolic disease
16. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis
17. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
18. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
19. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
20. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis
21. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: A randomised trial
22. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
23. The long-term clinical course of acute deep venous thrombosis
24. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
25. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
26. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis
27. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
28. New antithrombotic agents